Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
POSTED
12-08-22
POSTED
12-02-22
POSTED
09-23-22
POSTED
09-21-22
POSTED
06-29-22
POSTED
06-23-22
POSTED
06-15-22
POSTED
05-24-22
POSTED
05-16-22
POSTED
04-25-22